Inventprise
A clinical-stage vaccine company, Inventprise uses its proprietary linker technology to develop vaccines, including its lead candidate, IVT PCV-25.
Secondary Market Price
How Inventprise Measures Up
To help you manage your Inventprise equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Inventprise's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Inventprise Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Inventprise's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Inventprise is a clinical-stage vaccine company headquartered in Redmond, Washington, that develops and manufactures vaccines. The company's primary focus is on its lead candidate, IVT PCV-25, a pneumococcal conjugate vaccine for pediatric use created with its proprietary Linker Conjugation Platform. Alongside its work on conjugate vaccines, Inventprise is also involved in mRNA vaccine development and operates automated manufacturing facilities. Specific details about the company's history, including its founding date and founders, are not publicly available.
The company's future plans involve advancing its IVT PCV-25 vaccine and expanding its mRNA vaccine program. In May 2025, Inventprise announced it had selected Quantoom Biosciences’ Ntensify® Production Technology to support its mRNA development. The following month, the company reported a breakthrough in a COVID-19 conjugate vaccine study, with the results published in the Vaccine Journal. Earlier in the year, in January 2025, Inventprise was mentioned in an announcement from Life Science Washington as the state's life sciences industry grew its position as a top U.S. cluster.
- Bill Gates
- Melinda French Gates
- Warren Buffett
- Co-Founder, Subhash Kapre
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Inventprise worth joining?
Deciding if a company is worth joining depends on your personal career goals and financial situation. Tools like Prospect can help you analyze the value of your equity offer to make a more informed decision.
What should I do with my Inventprise stock?
Managing private company stock involves complex decisions about when to exercise options, sell shares, or hold for future growth. Platforms like Prospect can provide data-driven strategies to help you navigate these choices and optimize your financial outcome.
Can you sell Inventprise stock?
As a private company, Inventprise stock isn't traded on a public exchange, but you may be able to sell shares through company-approved tender offers or on secondary markets. Prospect offers tools to help you decide how much to sell and which shares are most tax-efficient.
How can I find the value of my Inventprise stock?
The value of private stock is typically determined by a 409A valuation, but its future worth can be difficult to predict. You can use predictive models from platforms like Prospect, which analyze various data points to forecast your equity's potential value.
What is Inventprise's equity worth?
The total worth of Inventprise's equity is based on its latest private valuation, which can change with new funding rounds or business performance. To understand what your specific holdings might be worth, you can use tools like Prospect to model different financial outcomes.
What is Inventprise's stock ticker symbol?
Inventprise is a private company, so it does not have a stock ticker symbol and is not traded on public stock exchanges. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO).
Can I buy or sell Inventprise stock?
Selling private stock is typically restricted to specific events like tender offers, while buying it is usually limited to accredited investors in private funding rounds. If you are an employee with equity, a platform like Prospect can help you create a strategy for when and how to sell your shares.
What is the criteria to buy or invest in Inventprise stock?
Investing in a private company like Inventprise is generally restricted to accredited investors during specific funding rounds or for employees receiving equity compensation. If you are an employee, tools like Prospect can help you manage your equity but are not a platform for outside investment.
